Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM P/E Multiple | -13.3x - -14.7x | -14.0x |
Selected Fwd P/E Multiple | -23.0x - -25.4x | -24.2x |
Fair Value | $0.49 - $0.54 | $0.52 |
Upside | 66.8% - 84.4% | 75.6% |
Benchmarks | - | Full Ticker |
CANbridge Pharmaceuticals Inc. | 122,800.0% | SEHK:1228 |
Guanhao Biotech Co.,Ltd. | 30,023,800.0% | SZSE:300238 |
Keymed Biosciences Inc. | 216,200.0% | SEHK:2162 |
Jiangsu Aidea Pharmaceutical Co., Ltd. | 68,848,800.0% | SHSE:688488 |
Abbisko Cayman Limited | 225,600.0% | SEHK:2256 |
Jacobio Pharmaceuticals Group Co., Ltd. | - | OTCPK:JBPH.F |
- | - | - |
Select Price / LTM EPS Ratio | ||||||||
Benchmark Companies | ||||||||
1228 | 300238 | 2162 | 688488 | 2256 | JBPH.F | |||
SEHK:1228 | SZSE:300238 | SEHK:2162 | SHSE:688488 | SEHK:2256 | OTCPK:JBPH.F | |||
Historical Net Income Growth | ||||||||
5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
3Y CAGR | NM- | -28.1% | NM- | NM- | NM- | NM- | ||
Latest Twelve Months | -16.8% | 19.8% | -43.4% | -24.2% | 106.6% | 56.6% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | -1969.4% | -22.1% | -1064.1% | -18.3% | -4294.5% | -414.6% | ||
Prior Fiscal Year | -368.3% | 7.7% | -101.5% | -18.5% | -2264.3% | -565.4% | ||
Latest Fiscal Year | -520.1% | 7.3% | -120.3% | -33.8% | 5.6% | -100.0% | ||
Latest Twelve Months | -520.1% | 7.3% | -120.3% | -21.4% | 5.6% | -100.0% | ||
Current Trading Multiples | ||||||||
EV / LTM EBITDA | -1.3x | 78.2x | -19.6x | -117.7x | -330.3x | -12.5x | ||
Price / LTM Sales | 3.4x | 11.2x | 28.9x | 11.7x | 10.9x | 21.8x | ||
LTM P/E Ratio | -0.6x | 152.6x | -24.0x | -54.7x | 194.1x | -21.8x | ||
Low | Mid | High | ||||||
Benchmark LTM P/E Ratio | -54.7x | -0.6x | 194.1x | |||||
Historical LTM P/E Ratio | -21.8x | -10.7x | -6.8x | |||||
Selected P/E Multiple | -13.3x | -14.0x | -14.7x | |||||
(x) LTM Net Income | (156) | (156) | (156) | |||||
(=) Equity Value | 2,071 | 2,180 | 2,289 | |||||
(/) Shares Outstanding | 653.5 | 653.5 | 653.5 | |||||
Implied Value Range | 3.17 | 3.34 | 3.50 | |||||
FX Rate: CNY/USD | 7.2 | 7.2 | 7.2 | Market Price | ||||
Implied Value Range (Trading Cur) | 0.44 | 0.47 | 0.49 | 0.30 | ||||
Upside / (Downside) | 49.9% | 57.8% | 65.7% |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | 1228 | 300238 | 2162 | 688488 | 2256 | JBPH.F | |
Value of Common Equity | 287 | 4,256 | 12,362 | 6,127 | 5,492 | 1,382 | |
(/) Shares Outstanding | 424.6 | 265.2 | 294.6 | 420.8 | 616.2 | 653.5 | |
Implied Stock Price | 0.68 | 16.05 | 41.96 | 14.56 | 8.91 | 2.11 | |
FX Conversion Rate to Trading Currency | 0.91 | 1.00 | 0.91 | 1.00 | 0.91 | 7.17 | |
Implied Stock Price (Trading Cur) | 0.74 | 16.05 | 45.95 | 14.56 | 9.76 | 0.30 | |
Trading Currency | HKD | CNY | HKD | CNY | HKD | USD | |
FX Rate to Reporting Currency | 0.91 | 1.00 | 0.91 | 1.00 | 0.91 | 7.17 |